When are HDL-cholesterol and LDL-cholesterol subfractions useful?
The importance of lipoprotein analysis is in the evaluation of risk for individuals assessed for primary prevention of IHD. Patients with proven IHD should be given lipid lowering therapy with an aim of maintaining total cholesterol < 4.8 mmol/L (or LDL-cholesterol < 3.2 mmol/L). All patients starting lipid lowering therapy should have a full lipid profile to ensure that the total cholesterol is due to LDL-cholesterol and not HDL-cholesterol or triglyceride-rich particles. Raised HDL-cholesterol is particularly relevant for women who may retain a high HDL-cholesterol for many years after the menopause.
